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Recent studies have made significant advances in under-
standing the mechanisms of gut microbiota involved in
human health and disease [1, 2]. Now the gut microbiota has
been recognized as a key player in a broad spectrumof human
diseases from obesity associated liver and cardiovascular
diseases to mental development and psychiatric diseases [3,
4]. Accordingly, modulations of gut microbial diversity and
composition are expected to improve human health and to
provide novel therapeutic modalities for human disease. The
gut microbial modulators can be simply specific diets and
drinks, natural tea and Chinese herbs, or specialized prebi-
otics and probiotics.
In this special issue, authors presented a number of very
interesting studies on changes of gut microbiota in diges-
tive diseases. These review and original articles of research
and clinical studies cover a range of topics, including the
pathogenesis of alcoholic and nonalcoholic fatty liver diseases
(NAFLD), the outcome of intestinal bacterial translocation
in advanced cirrhosis, the gut microbiota changes in an
animal colitis model after treatment with a monoclonal
antibody, and fecal microbiota transplantation (FMT) in
elderly patients with refractoryClostridium difficile infection.
In these articles, authors have described mechanisms of
disease development as well as therapeutic effects of specific
antibodies, probiotics, and FMT.
While we know the simple cause of alcoholic fatty
liver disease (AFLD), its pathogenesis is complicated and it
involves a wide range of changes in host metabolism and gut
microbiota. Certainly, removal of the cause (alcohol abuse)
is the first treatment for AFLD, and the use of probiotics can
ameliorate its development as shown in recent clinical and
animal studies [5–7]. Although sharing many pathological
and clinical features with AFLD, NAFLD does not have
a simple, single cause. Instead, NAFLD is the result of
interactions between gut microbiota, host genetics, and diet.
There have been a number of studies evaluating the effects
and mechanisms of probiotics [8–10], natural tea [11, 12],
and Chinese herbs/recipes [13, 14] on AFLD and NAFLD.
These studies reported beneficial effects with promising
perspectives for future development of novel therapeutic
strategies.
However, in light of the nature of gut microbiota being
highly diverse and constitutional, built during the early
life of individuals, cautious optimism is necessary for any
future therapeutic developments aiming at modulations of
gut microbiota, as we do not yet know long-term effects from
those initial efforts or indeed which of those microbiota and
metabolomics changes are contributory, causative, or simply
a cofounder in AFLD and NAFLD, or indeed any other
condition. Thus far, it is not clear whether the modulations
by specific diets and drinks including natural tea, even by
probiotics, are able to change the constitutional nature of
gut microbiota, although the relative abundance of microbial
species is altered upon administrating modulators [12, 13, 15].
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Moreover, current analytic strategies on metagenomics data
are focused on major changes in gut microbial compositions
and have not paid sufficient attention to or have even ignored
the changes in minor species with less than 1% abundance.
Furthermore, sampling of microbiota in intestinal lumen
may not necessarily represent the mucosal portion or the
whole population of gut flora [16]. In fact, the true signal
and messengers governing the alterations of gut microbiota
and host metabolism are largely elusive. Enteric short-
chain fatty acids (SCFAs), such as acetate, propionate, and
butyrate, are fermentation metabolites by intestinal bacteria.
Recent studies have suggested a messenger role of SCFAs in
several human diseases including metabolic syndrome [17]
and autism [4]. In short, careful designs of future studies
should take these factors and host genetic background under
consideration to discover the real effectors and to discern
the true effects of gut microbial modulators in alcoholic and
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